We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+8.08%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.07B
AUM Growth
+$64.2M
Cap. Flow
+$82M
Cap. Flow %
7.68%
Top 10 Hldgs %
64.05%
Holding
53
New
4
Increased
9
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$22.6M
2
MDCO
Medicines Co
MDCO
+$21.8M
3
INSM icon
Insmed
INSM
+$16.1M
4
CHMA
Chiasma, Inc. Common Stock
CHMA
+$15.6M
5
ZYME icon
Zymeworks
ZYME
+$15.3M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$26M
2
ACER
Acer Therapeutics Inc
ACER
+$14.1M
3
QURE icon
uniQure
QURE
+$10.8M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.55M
5
ZLAB icon
Zai Lab
ZLAB
+$2.11M

Sector Composition

Rank Sector Weight
1 Healthcare 94.71%
2 Materials 2.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$6.12B
$11.4M 1.07%
843,478
– –
OBSV
27
DELISTED
ObsEva SA Ordinary Shares
OBSV
$10.6M 0.99%
937,147
– –
NBRV
28
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$9.81M 0.92%
16,157
-1,458
-8% -$894K
APLS
29
DELISTED
Apellis Pharmaceuticals
APLS
$9.72M 0.91%
383,538
– –
VRNA
30
DELISTED
Verona Pharma
VRNA
$7.61M 0.71%
1,492,951
– –
GLMD icon
31
Galmed Pharmaceuticals
GLMD
$4.41M
$7.14M 0.67%
5,396
– –
DERM
32
DELISTED
Dermira, Inc.
DERM
$6.69M 0.63%
700,000
– –
KALA icon
33
KALA BIO
KALA
$12M
$6.65M 0.62%
418
– –
KRTX
34
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$6.51M 0.61%
+325,000
New +$6.51M
MTNB icon
35
Matinas BioPharma
MTNB
$1.99M
$5.84M 0.55%
136,364
– –
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
$5.02M 0.47%
105,000
– –
DTIL icon
37
Precision BioSciences
DTIL
$173M
$3.72M 0.35%
9,350
– –
ACRS icon
38
Aclaris Therapeutics
ACRS
$708M
$3.61M 0.34%
1,647,214
– –
GNCA
39
DELISTED
Genocea Biosciences, Inc.
GNCA
$2.46M 0.23%
626,401
-350,000
-36% -$1.83M
DBVT
40
DBV Technologies
DBVT
$796M
$2.22M 0.21%
27,000
– –
AGRX
41
DELISTED
Agile Therapeutics
AGRX
$2.21M 0.21%
757
– –
SRRA
42
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.36M 0.13%
60,957
– –
RNAC icon
43
Cartesian Therapeutics
RNAC
$218M
$977K 0.09%
18,202
– –
AKTX
44
Akari Therapeutics
AKTX
$14.8M
$699K 0.07%
432
– –
TMBR
45
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$189K 0.02%
529
-546
-51% -$426K
SLNOW
46
DELISTED
Soleno Therapeutics, Inc. Series A Warrant
SLNOW
$19K ﹤0.01%
188,772
– –
QURE icon
47
uniQure
QURE
$2.76B
– –
-180,336
Closed -$10.8M
ZLAB icon
48
Zai Lab
ZLAB
$2.06B
– –
-71,595
Closed -$2.11M
VIRX
49
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-2,841
Closed -$121K
TRVN
50
DELISTED
Trevena, Inc.
TRVN
– –
-1,974
Closed -$1.93M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Vivo Capital held 53 positions worth $1.07B, up 6.4% from $1B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Vivo Capital deployed $82M of net new capital in Q2 2019, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Medicines Co: 669,012 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 98% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Genocea Biosciences, Inc., an estimated $1.83M trimmed.

  • Vivo Capital's largest Q2 2019 buy was Medicines Co: 669,012 shares worth $24.4M.
  • Vivo Capital added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $22.6M increase.
  • Vivo Capital's biggest Q2 2019 reduction was Genocea Biosciences, Inc., cutting an estimated $1.83M.
  • Vivo Capital fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, selling an estimated $26M.
  • Vivo Capital's ten largest holdings make up 64% of its $1.07B portfolio in Q2 2019.
  • Vivo Capital opened 4 new positions and closed 7 in Q2 2019.
  • Vivo Capital's portfolio value rose 6.4% quarter-over-quarter to $1.07B.

Based on Vivo Capital's 13F filing for Q2 2019, filed 13 Aug 2019.